Seres Therapeutics Inc. (MCRB)
Seres Therapeutics Statistics
Share Statistics
Seres Therapeutics has 8.72M shares outstanding. The number of shares has increased by 0.72% in one year.
| Shares Outstanding | 8.72M |
| Shares Change (YoY) | 0.72% |
| Shares Change (QoQ) | 0.22% |
| Owned by Institutions (%) | 41.32% |
| Shares Floating | n/a |
| Failed to Deliver (FTD) Shares | 5,412 |
| FTD / Avg. Volume | 7.53% |
Short Selling Information
The latest short interest is 15.26M, so 175.07% of the outstanding shares have been sold short.
| Short Interest | 15.26M |
| Short % of Shares Out | 175.07% |
| Short % of Float | 285.29% |
| Short Ratio (days to cover) | 11.96 |
Valuation Ratios
The PE ratio is 18990.89 and the forward PE ratio is -41.12. Seres Therapeutics's PEG ratio is -189.72.
| PE Ratio | 18990.89 |
| Forward PE | -41.12 |
| PS Ratio | 0 |
| Forward PS | n/a |
| PB Ratio | 187.37 |
| P/FCF Ratio | -17.34 |
| PEG Ratio | -189.72 |
Enterprise Valuation
Seres Therapeutics has an Enterprise Value (EV) of 2.64B.
| EV / Sales | 0 |
| EV / EBITDA | -21.79 |
| EV / EBIT | -17.79 |
| EV / FCF | -17.74 |
Financial Position
The company has a current ratio of 0.94, with a Debt / Equity ratio of 6.65.
| Current Ratio | 0.94 |
| Quick Ratio | 0.94 |
| Debt / Equity | 6.65 |
| Debt / EBITDA | -0.76 |
| Debt / FCF | -0.62 |
| Interest Coverage | 0 |
Financial Efficiency
Return on Equity is 0.99% and Return on Invested Capital is -113.1%.
| Return on Equity | 0.99% |
| Return on Assets | 0.1% |
| Return on Invested Capital | -113.1% |
| Revenue Per Employee | n/a |
| Profits Per Employee | $1,320.39 |
| Employee Count | 103 |
| Asset Turnover | 0 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | 0% |
Stock Price Statistics
The stock price has increased by -57.25% in the last 52 weeks. The beta is 2.53, so Seres Therapeutics's price volatility has been higher than the market average.
| Beta | 2.53 |
| 52-Week Price Change | -57.25% |
| 50-Day Moving Average | 12.84 |
| 200-Day Moving Average | 16.62 |
| Relative Strength Index (RSI) | 42.81 |
| Average Volume (20 Days) | 71,909 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -121.31M |
| Net Income | 136K |
| EBITDA | -121.31M |
| EBIT | n/a |
| Earnings Per Share (EPS) | 0 |
Balance Sheet
The company has 30.79M in cash and 91.64M in debt, giving a net cash position of -60.85M.
| Cash & Cash Equivalents | 30.79M |
| Total Debt | 91.64M |
| Net Cash | -60.85M |
| Retained Earnings | -978.1M |
| Total Assets | 139.81M |
| Working Capital | -2.55M |
Cash Flow
In the last 12 months, operating cash flow was -148.61M and capital expenditures -380K, giving a free cash flow of -148.99M.
| Operating Cash Flow | -148.61M |
| Capital Expenditures | -380K |
| Free Cash Flow | -148.99M |
| FCF Per Share | -0.96 |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
MCRB does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | 0.01% |
| FCF Yield | -5.77% |
Analyst Forecast
The average price target for MCRB is $25, which is 163.4% higher than the current price. The consensus rating is "Hold".
| Price Target | $25 |
| Price Target Difference | 163.4% |
| Analyst Consensus | Hold |
| Analyst Count | 5 |
Stock Splits
The last stock split was on Apr 22, 2025. It was a backward split with a ratio of 1:20.
| Last Split Date | Apr 22, 2025 |
| Split Type | backward |
| Split Ratio | 1:20 |
Scores
| Altman Z-Score | -12.54 |
| Piotroski F-Score | 3 |